REPORT ID 13484

EMEA (Europe, Middle East and Africa) Migraine Drugs Market Report 2017

Publish Date
21-Nov-17
Pages
112
Format
Electronic (PDF)

In this report, the EMEA Migraine Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Migraine Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Migraine Drugs market competition by top manufacturers/players, with Migraine Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca Plc.
    Allergan Plc.
    Pfizer, Inc.
    Teva Pharmaceutical Industries Ltd.
    GlaxoSmithKline Plc
    Eli Lilly & Co.
    Novartis AG
    Merck & Co., Inc.
    Valeant Pharmaceutical International, Inc.
    Janssen Pharmaceutical Company (Johnson & Johnson)
    Endo Pharmaceuticals Inc.
    Zosano Pharma Corporation
    Alder BioPharmaceuticals Inc.
    Avanir Pharmaceuticals, Inc.
    Eisai Co., Ltd.

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Oral
    Injectable
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Migraine Drugs for each application, including
    Retail Pharmacies
    Hospital Pharmacies
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Migraine Drugs Market Report 2017
1 Migraine Drugs Overview
    1.1 Product Overview and Scope of Migraine Drugs
    1.2 Classification of Migraine Drugs
        1.2.1 EMEA Migraine Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Migraine Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Oral
        1.2.4 Injectable
        1.2.5 Others
    1.3 EMEA Migraine Drugs Market by Application/End Users
        1.3.1 EMEA Migraine Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Retail Pharmacies
        1.3.3 Hospital Pharmacies
        1.3.4 Others
    1.4 EMEA Migraine Drugs Market by Region
        1.4.1 EMEA Migraine Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Migraine Drugs (2012-2022)
        1.5.1 EMEA Migraine Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Migraine Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Migraine Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Migraine Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Migraine Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Migraine Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Migraine Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Migraine Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Migraine Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Migraine Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Migraine Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Migraine Drugs (Volume) by Application
    2.4 EMEA Migraine Drugs (Volume and Value) by Region
        2.4.1 EMEA Migraine Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Migraine Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Migraine Drugs Sales Price by Region (2012-2017)

3 Europe Migraine Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Migraine Drugs Sales and Value (2012-2017)
        3.1.1 Europe Migraine Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Migraine Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Migraine Drugs Sales and Market Share by Type
    3.3 Europe Migraine Drugs Sales and Market Share by Application
    3.4 Europe Migraine Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Migraine Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Migraine Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Migraine Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Migraine Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Migraine Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Migraine Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Migraine Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Migraine Drugs Sales and Growth Rate (2012-2017)

4 Middle East Migraine Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Migraine Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Migraine Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Migraine Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Migraine Drugs Sales and Market Share by Type
    4.3 Middle East Migraine Drugs Sales and Market Share by Application
    4.4 Middle East Migraine Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Migraine Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Migraine Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Migraine Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Migraine Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Migraine Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Migraine Drugs Sales and Growth Rate (2012-2017)

5 Africa Migraine Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Migraine Drugs Sales and Value (2012-2017)
        5.1.1 Africa Migraine Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Migraine Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Migraine Drugs Sales and Market Share by Type
    5.3 Africa Migraine Drugs Sales and Market Share by Application
    5.4 Africa Migraine Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Migraine Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Migraine Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Migraine Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Migraine Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Migraine Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Migraine Drugs Sales and Growth Rate (2012-2017)

6 EMEA Migraine Drugs Manufacturers/Players Profiles and Sales Data
    6.1 AstraZeneca Plc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Migraine Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 AstraZeneca Plc. Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Allergan Plc.
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Migraine Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Allergan Plc. Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Pfizer, Inc.
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Migraine Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Pfizer, Inc. Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Teva Pharmaceutical Industries Ltd.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Migraine Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Teva Pharmaceutical Industries Ltd. Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 GlaxoSmithKline Plc
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Migraine Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 GlaxoSmithKline Plc Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Eli Lilly & Co.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Migraine Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Eli Lilly & Co. Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Novartis AG
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Migraine Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Novartis AG Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Merck & Co., Inc.
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Migraine Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Merck & Co., Inc. Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Valeant Pharmaceutical International, Inc.
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Migraine Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Valeant Pharmaceutical International, Inc. Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Janssen Pharmaceutical Company (Johnson & Johnson)
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Migraine Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Janssen Pharmaceutical Company (Johnson & Johnson) Migraine Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Endo Pharmaceuticals Inc.
    6.12 Zosano Pharma Corporation
    6.13 Alder BioPharmaceuticals Inc.
    6.14 Avanir Pharmaceuticals, Inc.
    6.15 Eisai Co., Ltd.

7 Migraine Drugs Manufacturing Cost Analysis
    7.1 Migraine Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Migraine Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Migraine Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Migraine Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Migraine Drugs Market Forecast (2017-2022)
    11.1 EMEA Migraine Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Migraine Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Migraine Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Migraine Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Migraine Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Migraine Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Migraine Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Migraine Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Migraine Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Migraine Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer